Clinical trial
A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC
NCT04514835 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 1, 2021
- Completion date
- January 31, 2023
- Enrollment
- 44 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.